or Try an Advanced Search...

    Exosome Stocks List

    Symbol Grade Name % Change
    COYA C Coya Therapeutics, Inc. -2.63
    PRTC D PureTech Health plc 2.36
    AEMD F Aethlon Medical, Inc. -0.88
    ALBT F Avalon GloboCare Corp. -6.07
    View As Page of Charts
    Related Industries: Biotechnology Medical Care Scientific & Technical Instruments
    Related Stock Lists: Medicine Biology Biotechnology Cell Therapy Immunology Vesicles Alzheimer's Disease Amyotrophic Lateral Sclerosis Antiviral Drug Biomarker Technology Biomarkers Biopharmaceutical Bioproduction Cancer Central Nervous System Disorders Choline Chronic Disease Clinical Medicine Cognitive Dysfunction Coronavirus

    Related ETFs - A few ETFs which own one or more of the above listed Exosome stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.03
    View all Exosome ETFs...
    Compare ETFs

        Exosome Stocks Recent News

        Date Stock Title
        Nov 1 COYA Coya Therapeutics names Arun Swaminathan as CEO
        Nov 1 COYA Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
        Oct 31 COYA Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
        Oct 31 ALBT Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
        Oct 30 COYA Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
        Oct 30 PRTC PureTech to Present at Two Upcoming Investor Conferences
        Oct 29 COYA Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
        Oct 29 COYA Coya stock tumbles 23% on mixed results from Alzheimer's study
        Oct 29 AEMD Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
        Oct 29 COYA Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
        Oct 28 COYA Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
        Related Industries: Biotechnology Medical Care Scientific & Technical Instruments
        Related Stock Lists: Medicine Biology Biotechnology Cell Therapy Immunology Vesicles Alzheimer's Disease Amyotrophic Lateral Sclerosis Antiviral Drug Biomarker Technology Biomarkers Biopharmaceutical Bioproduction Cancer Central Nervous System Disorders Choline Chronic Disease Clinical Medicine Cognitive Dysfunction Coronavirus
        Exosome

        Browse All Tags